Article

[Management of bladder cancer in unfit patients].

Service Urologie, Hôpital Saint Louis 1, avenue Claude-Vellefaux, Paris cedex 10, France.
Progrès en Urologie (impact factor: 0.58). 03/2010; 20 Suppl 1:S54-6. DOI:10.1016/S1166-7087(10)70028-2 pp.S54-6
Source: PubMed

ABSTRACT Adjuvant therapies in bladder cancer are based on risk of recurrence and associated comorbidities (renal failure). Lymph node involvement is the most important prognostic factor for decision. Two adjuvant chemotherapies exist: MVAC or GC. In unfit patients, association (Gemcitabine and Taxanes) could be proposed. Indication of adjuvant radiotherapy depends on metastatic risk and resection margins. Concomitant chemotherapy and radiotherapy should be proposed to selected patients who refuse or are not candidate for radical cystectomy.

0 0
 · 
0 Bookmarks
 · 
25 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

adjuvant chemotherapies
 
adjuvant radiotherapy
 
Adjuvant therapies
 
comorbidities
 
GC
 
Gemcitabine
 
Lymph node involvement
 
metastatic risk
 
patients
 
prognostic factor
 
radical cystectomy
 
resection margins
 
unfit patients